BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

903 related articles for article (PubMed ID: 16586109)

  • 21. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease.
    Allen U; Hebert D; Petric M; Tellier R; Tran D; Superina R; Stephens D; West L; Wasfy S; Nelson S
    Clin Infect Dis; 2001 Jul; 33(2):145-50. PubMed ID: 11418872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications.
    Schaffer K; Hassan J; Staines A; Coughlan S; Holder P; Tuite G; McCormick AP; Traynor O; Hall WW; Connell J
    Liver Transpl; 2011 Dec; 17(12):1420-6. PubMed ID: 21837744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients.
    Babel N; Schwarzmann F; Pruss A; Volk HD; Reinke P
    Transplant Proc; 2004 Nov; 36(9):2679-82. PubMed ID: 15621122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study.
    Johnson LR; Nalesnik MA; Swerdlow SH
    Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
    J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe cold agglutinin disease caused by recurrent monomorphic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD), clonally related to an EBV-negative plasmacytic hyperplasia in a pediatric multivisceral organ transplant recipient.
    Brunner B; Kropshofer G; Ellemunter H; Brunner A; Mueller T; Margreiter R; Tzankov A
    Pediatr Transplant; 2007 Aug; 11(5):547-51. PubMed ID: 17631026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
    Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
    Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
    Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders.
    Jabs WJ; Hennig H; Kittel M; Pethig K; Smets F; Bucsky P; Kirchner H; Wagner HJ
    J Clin Microbiol; 2001 Feb; 39(2):564-9. PubMed ID: 11158107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.
    Benden C; Aurora P; Burch M; Cubitt D; Lloyd C; Whitmore P; Neligan SL; Elliott MJ
    J Heart Lung Transplant; 2005 Dec; 24(12):2103-8. PubMed ID: 16364857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection.
    Ahya VN; Douglas LP; Andreadis C; Arnoldi S; Svoboda J; Kotloff RM; Hadjiliadis D; Sager JS; Woo YJ; Pochettino A; Schuster SJ; Stadtmauer EA; Tsai DE
    J Heart Lung Transplant; 2007 Aug; 26(8):839-44. PubMed ID: 17692789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OKT3 and ganciclovir treatments are possibly related to the presence of Epstein-Barr virus in serum after liver transplantation.
    Barkholt L; Linde A; Falk KI
    Transpl Int; 2005 Jul; 18(7):835-43. PubMed ID: 15948864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
    Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
    Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.